ArticleCancer imaging : the official publication of the International Cancer Imaging Society2024
Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.European journal of nuclear medicine and molecular imaging · 2025Trial
- Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Preoperative prediction of Ki-67 expression in breast cancer using a combined radiomics model based on 18F-FDG PET/CT.Medicine · 2026Article
- Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types usingEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Personalized prediction of breast cancer candidates for Anti-HER2 therapy usingFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRecent advancements in novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have highlighted the emerging HER2-low breast cancer subtype with promising therapeutic efficacy. This study aimed to comparatively analyze the metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using baseline fluorine-18 fluorodeoxyglucose (
methodsConsecutive patients with newly diagnosed breast cancer who underwent
resultsIn total, 258 patients (mean age: 54 ± 12 years) were included. In hormone receptor (HR)-positive subgroup, SUVmax and TLR were significantly higher in HER2-low than in HER2-zero (P = 0.045 and 0.03, respectively). But in HR-negative subgroup, there was no significant metabolic difference between HER2-low and HER2-zero (All P > 0.05). The four metabolic parameters were significant predictors of DFS in HER2-negative patients (All P < 0.01), but there was no significant difference in DFS between HER2-low and -zero, regardless of tumor metabolism. Moreover, in HER2-zero patients, the DFS of patients with high metabolism was significantly shorter than that of patients with low metabolism (P
conclusionOur study demonstrated the HR-positive HER2-low breast cancer exhibited a particularity in glucose metabolic profile. Additionally, HER2-zero patients with elevated metabolism were associated with inferior prognosis and warranted careful attention in clinical evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.